Cited by 110Lung Cancer Treatments and MutationsHER2/EGFR in Cancer ResearchCancer Genomics and Diagnostics

The DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.

Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance

Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki·2013·Lung Cancer

DOI 10.1016/j.lungcan.2013.01.018

Open this paper in CoChat — free account

Abstract

Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated dramatic tumor responses and favorable clinical outcomes in a select group of non-small cell lung cancer (NSCLC) patients whose tumors harbor EGFR activating mutations. The best characterized of the mutations conferring sensitivity to EGFR tyrosine kinase inhibitors (TKIs) are deletions in exon 19 and a point mutation in exon 21 (L858R). Likewise, the most common mutation that confers resistance is the T790M point mutation. However several other mutations have been reported and several have been characterized as regards their role in sensitivity or resistance to EGFR TKIs. Resistance to the EGFR TKIs erlotinib and gefitinib, and the newer irreversible EGFR TKIs is a problem of fundamental importance. Recognition of the presence and significance of specific EGFR mutations is important for appropriate therapeutic implementation of EGFR TKIs and research and development of mutation-specific inhibitors. We summarize the literature and present an overview of the subject of less common EGFR mutations and their clinical significance, with an emphasis on EGFR TKI sensitivity or resistance.

Integrity signals

Registry

Crossref · 10.1016/j.lungcan.2013.01.018

Cites

83 of 83 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citation
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
High density synthetic oligonucleotide arrays
Lipshutz, R. J., Fodor, S. P. A., Gingeras, T., & Lockhart, D. J. (1999) · Nature Genetics · doi:10.1038/4447 · Cited by 2,204
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650

Flagged first, then by citations

Show all 86 references

3 of the 86 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Shih, 2011, Activity of BIBW 2992, an irreversible EGFR/HER1 TKI, in lung adenocarcinoma patients harboring less common EGFR mutations, Ann Oncol, 21, 415
Horn, 2011, Activity and tolerability of combined EGFR targeting wih afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. J Thorac Oncol, 6, S39

Sorted by citations

The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. J. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,408
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
Roskoski, R. J. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.11.014 · Cited by 502
Structure-based classification predicts drug response in EGFR-mutant NSCLC
Robichaux, J. P., Le, X., Vijayan, R. S. K., Hicks, J. K., Heeke, S., Elamin, Y. Y., Lin, H. Y., Udagawa, H., Skoulidis, F., Tran, H., et al. (2021) · Nature · doi:10.1038/s41586-021-03898-1 · Cited by 490
EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
Dong, Z.-Y., Zhang, J.-T., Liu, S.-Y., Su, J., Zhang, C., Xie, Z., Zhou, Q., Tu, H.-Y., Xu, C.-R., Yan, L.-X., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1356145 · Cited by 440
Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network
Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt418 · Cited by 324
ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
Roskoski, R. J. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.001 · Cited by 226
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A., Leighl, N. B., Blackhall, F. H., Popat, S., Kerr, K. M., Ahn, M., Arcila, M. E., Arrieta, O. G., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 209
Self-citation
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
Zhou, F., Guo, H., Xia, Y., Le, X., Tan, D. S. W., Ramalingam, S. S., & Zhou, C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00971-2 · Cited by 230
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173
Efficacy and safety of first line treatments for patients with advanced epidermal growth factor receptor mutated, non-small cell lung cancer: systematic review and network meta-analysis
Zhao, Y., Liu, J., Cai, X., Pan, Z., Liu, J., Yin, W., Chen, H., Xie, Z., Liang, H., Wang, W., et al. (2019) · BMJ · doi:10.1136/bmj.l5460 · Cited by 170
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 157
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Gristina, V., Malapelle, U., Galvano, A., Pisapia, P., Pepe, F., Rolfo, C. D., Tortorici, S., Bazan, V., Troncone, G., & Russo, A. D. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101994 · Cited by 124
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Elamin, Y. Y., Robichaux, J. P., Carter, B. W., Altan, M., Tran, H. T., Gibbons, D. L., Heeke, S., Fossella, F. V., Lam, V. K. L., Le, X., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.06.006 · Cited by 112
Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical Scenario
Russo, A., Franchina, T., Ricciardi, G., Battaglia, A., Picciotto, M., & Adamo, V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061431 · Cited by 110
Targeting EGFR in Lung Cancer: Current Standards and Developments
Díaz-Serrano, A., Gella, P., Jiménez, E., Zugazagoitia, J., & Paz-Ares Rodríguez, L. (2018) · Drugs · doi:10.1007/s40265-018-0916-4 · Cited by 108
Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review
Borgeaud, M., Parikh, K., Banna, G. L., Kim, F., Olivier, T., Le, X., & Addeo, A. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.03.016 · Cited by 108
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.107 · Cited by 98
Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations
Zonta, E., Garlan, F., Pécuchet, N., Perez‐Toralla, K., Caën, O., Milbury, C. A., Didelot, A., Fabre, E., Blons, H., Laurent‐Puig, P., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159094 · Cited by 97
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
Xu, J., Jin, B., Chu, T., Dong, X., Yang, H., Zhang, Y., Wu, D., Lou, Y., Zhang, X., Wang, H., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.01.018 · Cited by 92
Common EGFR -Mutated Subgroups (Del19/L858R) in Advanced Non-Small-Cell Lung Cancer: Chasing Better Outcomes with Tyrosine Kinase Inhibitors
Reguart, N., & Remon, J. (2015) · Future Oncology · doi:10.2217/fon.15.15 · Cited by 91
PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy
Chen, K., Cheng, G., Zhang, F., Zhu, G., Xu, Y., Yu, X., Huang, Z., & Fan, Y. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.010 · Cited by 89
Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: A retrospective analysis in Korea
Baek, J. H., Sun, J., Min, Y. J., Cho, E. K., Cho, B. C., Kim, J.-H., Ahn, M., & Park, K. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.11.013 · Cited by 85
Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
Du, Y.-F., Karatekin, F., Wang, W. K., Hong, W., & Gandhi, T. K. B. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100076 · Cited by 88
Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma
Lohinai, Z., Hoda, M. A., Fábián, K., Ostoros, G., Rásó, E., Barbai, T., Tı́már, J., Kovalszky, I., Cserepes, M., Rózsás, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000492 · Cited by 79
EGFR–Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors
Barnet, M. B., O'Toole, S. A., Horvath, L. G., Selinger, C. I., Yu, B., Ng, C. C., Boyer, M. J., Cooper, W. A., & Kao, S. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.001 · Cited by 77
Current Approaches in NSCLC Targeting K-RAS and EGFR
Aran, V., & Omerović, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225701 · Cited by 74
Understanding EGFR heterogeneity in lung cancer
Passaro, A., Malapelle, U., Re, M. D., Attili, I., Russo, A., Guerini‐Rocco, E., Fumagalli, C., Pisapia, P., Pepe, F., Luca, C. D., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000919 · Cited by 75
Lipid rafts, KCa/ClCa/Ca2+ channel complexes and EGFR signaling: Novel targets to reduce tumor development by lipids?
Guéguinou, M., Gambade, A., Félix, R., Chantôme, A., Fourbon, Y., Bougnoux, P., Weber, G., Potier‐Cartereau, M., & Vandier, C. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.10.036 · Cited by 68
Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations
Passaro, A., Prelaj, A., Bonanno, L., Tiseo, M., Tuzi, A., Proto, C., Chiari, R., Rocco, D., Genova, C., Sini, C., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.11.005 · Cited by 54
Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
Karlsen, E., Kahler, S. L., Tefay, J., Joseph, S. R., & Simpson, F. (2021) · Cells · doi:10.3390/cells10051206 · Cited by 52
Analysis of clinically relevant somatic mutations in high-risk head and neck cutaneous squamous cell carcinoma
Zilberg, C., Lee, M. W., Yu, B., Ashford, B., Kraitsek, S., Ranson, M., Shannon, K. F., Cowley, M. J., Iyer, N. G., Palme, C. E., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.128 · Cited by 50
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors
Lee, J. Y., Ku, B. M., Lim, S. H., Lee, M., Kim, H., Kim, M., Kim, S., Jung, H. A., Sun, J., Ahn, J. S., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000535 · Cited by 48
Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study
Pilotto, S., Rossi, A., Vavalà, T., Follador, A., Tiseo, M., Galetta, D., Morabito, A., Di Maio, M., Martelli, O., Caffo, O., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.05.016 · Cited by 46
Non-small cell lung cancer patients with ex19del or exon 21 L858R mutation: distinct mechanisms, different efficacies to treatments
Li, W., & Cui, J. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03296-6 · Cited by 47
Structure-Based Network Analysis of Activation Mechanisms in the ErbB Family of Receptor Tyrosine Kinases: The Regulatory Spine Residues Are Global Mediators of Structural Stability and Allosteric Interactions
James, K. A., & Verkhivker, G. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113488 · Cited by 40
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non–Small-Cell Lung Cancer
Patil, T., Mushtaq, R. R., Marsh, S. A., Azelby, C. M., Pujara, M., Davies, K. D., Aisner, D. L., Purcell, W. T., Schenk, E. L., Pacheco, J. M., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.11.008 · Cited by 39
Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need
Pretelli, G., Spagnolo, C. C., Ciappina, G., Santarpía, M., & Pasello, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108878 · Cited by 39
Different characteristics and survival in non‐small cell lung cancer patients with primary and acquired EGFR T790M mutation
Wang, S., Yan, B., Zhang, Y., Xu, J., Qiao, R., Dong, Y., Zhang, B., Zhao, Y., Zhang, L., Qian, J., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32015 · Cited by 35
Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
Brindel, A., Althakfi, W., Barritault, M., Watkin, E., Maury, J., Bringuier, P., Girard, N., & Brevet, M. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd-19-3790 · Cited by 34
Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients
Chen, K., Yu, X., Wang, H., Huang, Z., Xu, Y., Gong, L., & Fan, Y. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3464-9 · Cited by 31
Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial
Markóczy, Z., Sárosi, V., Kudaba, I., Gálffy, G., Turay, Ü. Y., Demirkazık, A., Purkalne, G., Somfay, A., Pápai-Székely, Z., Rásó, E., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4283-z · Cited by 28
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory
Mao, L., Zhao, W., Li, X., Zhang, S., Zhou, C., Zhou, D., Ou, X., Xu, Y., Tang, Y., Ou, X., et al. (2021) · Pathology & Oncology Research · doi:10.3389/pore.2021.602726 · Cited by 32
EGFR and KRAS mutations in Chinese patients with sinonasal inverted papilloma and oncocytic papilloma
Wang, H., Li, H., Hu, L., Zhou, J., Zhai, C., Wang, D., & Sun, X. (2019) · Histopathology · doi:10.1111/his.13868 · Cited by 28
Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients
Ebert, E. B. F., McCulloch, T., Hansen, K. H., Linnet, H., Sørensen, B. S., & Meldgaard, P. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.03.020 · Cited by 26
Uncommon EGFR mutations associate with lower incidence of T790M mutation after EGFR-TKI treatment in patients with advanced NSCLC
Yang, S., Mao, S., Li, X., Zhao, C., Liu, Q., Yu, X., Wang, Y., Liu, Y., Pan, Y., Wang, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.11.018 · Cited by 26
Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes
Zhao, H., Li, S., Yang, Z., Peng, Y., Chen, X., & Zheng, J. (2018) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.079327 · Cited by 24
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
Li, T., Wang, S., Ying, J., Wang, Y., Hu, X., Hao, X., Xu, Z., Xing, P., & Li, J. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14156 · Cited by 22
Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non–Small-cell Lung Cancer
Kim, E. J.-H., Feldman, R. A., & Wistuba, I. I. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.08.001 · Cited by 23
Self-citation
Clinical Genotyping of Non–Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes
Tafe, L. J., Pierce, K. J., Peterson, J. D., Abreu, F. D., Memoli, V. A., Black, C. C., Pettus, J. R., Marotti, J. D., Gutmann, E. J., Liu, X., et al. (2016) · Neoplasia · doi:10.1016/j.neo.2016.07.010 · Cited by 21
The impact of rare EGFR mutations on the treatment response of patients with non-small cell lung cancer
Karachaliou, N., Molina‐Vila, M. Á., & Rosell, R. (2015) · Expert Review of Respiratory Medicine · doi:10.1586/17476348.2015.1046439 · Cited by 21
Potential mechanism of primary resistance to icotinib in patients with advanced non–small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi‐center study
Lei, L., Wang, W., Zhu, Y., Li, J., Fang, Y., Wang, H., Zhuang, W., Zhang, Y.-B., Wang, L., Fang, M., et al. (2019) · Cancer Science · doi:10.1111/cas.14277 · Cited by 20
Genetic determinants of lung cancer: Understanding the oncogenic potential of somatic missense mutations
Dhakar, R., Dakal, T. C., & Sharma, A. (2022) · Genomics · doi:10.1016/j.ygeno.2022.110401 · Cited by 19
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation
Hoshi, H., Hiyama, G., Ishikawa, K., Inageda, K., Fujimoto, J., Wakamatsu, A., Togashi, T., Kawamura, Y., Takahashi, N., Higa, A., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5227 · Cited by 18
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations
Frega, S., Lorenzi, M., Fassan, M., Indraccolo, S., Calabrese, F., Favaretto, A., Bonanno, L., Polo, V., Zago, G., Lunardi, F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15945 · Cited by 17
Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases
Roskoski, R. J. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.107036 · Cited by 19
New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
Wu, T., Hsiue, E. H.-C., Lee, J., Lin, C., & Yang, J. C. (2016) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1267569 · Cited by 16
Coexistence of sensitive and resistant epidermal growth factor receptor (EGFR) mutations in pretreatment non-small cell lung cancer (NSCLC) patients: First or third generation tyrosine kinase inhibitors (TKIs)?
Zhang, B., Xu, J., Zhang, X., Gu, P., Wang, H., Wang, S., Qian, J., Qiao, R., Zhang, Y., Yang, W., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.006 · Cited by 17
Mutational Portrait of Lung Adenocarcinoma in Brazilian Patients: Past, Present, and Future of Molecular Profiling in the Clinic
Freitas, H., Torrezan, G. T., da Cunha, I. W., de Macêdo, M. P., de Sá, V. K., Corassa, M. P., Ferreira, E. N., Saito, A. O., Molin, G. Z. D., de Lima, V. C. C., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01068 · Cited by 16
Verification of Wild-Type EGFR Status in Non–Small Cell Lung Carcinomas Using a Mutant-Enriched PCR on Selected Cases
Chen, Y.-L., Lu, C., Yang, S.-C., Su, W., Lin, Y.-L., Chen, W.-L., Huang, W., Su, W., Chow, N.-H., & Ho, C. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2014.05.007 · Cited by 15
EGFR mutation status in a series of Turkish non-small cell lung cancer patients
Calibasi‐Kocal, G., Amirfallah, A., Sever, T., Ünal, O. Ü., Gürel, D., Öztop, İ., Ellıdokuz, H., & Başbınar, Y. (2020) · Biomedical Reports · doi:10.3892/br.2020.1308 · Cited by 16
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters
Zeng, Y., Guo, T., Zhou, Y., Zhao, Y., Chu, L., Chu, X., Yang, X., Ni, J., & Zhu, Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-09245-5 · Cited by 13
Successful treatment of a patient with NSCLC carrying uncommon compound EGFR G719X and S768I mutations using osimertinib: A case report
Cai, Y., Wang, Y., Sun, J., Wang, X., Xu, Y., Sun, C., Guo, Y., Sun, M., & Ma, K. (2020) · Journal of International Medical Research · doi:10.1177/0300060520928793 · Cited by 13
A Cyclized Bivalent Aptamer-Based Protein Degrader Targeting Receptor Tyrosine Kinases Overcomes Resistance to Inhibitors in Lung Cancer
Wu, S., Zhou, X., Ai, L., Shang, Y., Yan, Y., Zhao, Z., & Tan, W. (2025) · ACS Nano · doi:10.1021/acsnano.5c03120 · Cited by 12
A macrocyclic kinase inhibitor overcomes triple resistant mutations in EGFR-positive lung cancer
Suzuki, M., Uchibori, K., Oh‐hara, T., Nomura, Y., Suzuki, R., Takemoto, A., Araki, M., Matsumoto, S., Sagae, Y., Kukimoto‐Niino, M., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00542-9 · Cited by 18
Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunitiesPreprint
Zhang, H., Liu, C., Wang, S., Wang, Q., Xu, F., Jiang, H., Li, X., Luo, C., Zhang, L., Hou, F., et al. (2024) · eLife · doi:10.7554/elife.95453.3 · Cited by 17
Lung Adenocarcinoma with Pulmonary Miliary Metastases and Complex Somatic Heterozygous EGFR Mutation
Schaller, A., Beau‐Faller, M., Mennecier, B., Renaud-Picard, B., Weingertner, N., Massard, G., & Quoix, É. (2014) · Case Reports in Oncology · doi:10.1159/000369526 · Cited by 12
Front-Line Therapy in EGFR Exon 19 Deletion and 21 Leu858Arg Mutations in Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
Xie, T., Zou, Z., Liu, C., Zhu, Y., Xu, Z., Wang, L., Li, J., & Xing, P. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9311875 · Cited by 10
Design, synthesis and biological evaluation of novel 3,4-dihydro-2H-[1,4]oxazino [2,3-f]quinazolin derivatives as EGFR-TKIs
Qin, X., Liu, P., Li, Y., Hu, L., Liao, Y.-X., Cao, T., & Yang, L. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129104 · Cited by 11
Patients with advanced non‑small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real‑world data analysis
Chang, N., Duan, J., Wang, L., Dong, Z., & Liu, Z. (2020) · Oncology Letters · doi:10.3892/ol.2020.11801 · Cited by 11
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
Chan, S.-K., Choi, C., & Lee, V. H.-F. (2022) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2022.100322 · Cited by 10
Tumor evolution in epidermal growth factor receptor mutated non-small cell lung cancer
Velázquez, A. I., & McCoach, C. E. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.31 · Cited by 9
Suppression of Chromosome Instability Limits Acquired Drug Resistance
Crowley, E. A., Hermance, N. M., Herlihy, C. P., & Manning, A. L. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0263 · Cited by 8
Two non-small cell lung cancer (NSCLC) patients with brain metastasis harboring epidermal growth factor receptor (EGFR) G719X and L861Q mutations benefited from aumolertinib: two cases report and review of the literature
Li, L. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10407 · Cited by 8
Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses
Kuan, A. S., Chiang, C., Wu, H., Yang, H., Chen, C., Lin, C., Guo, W., Pan, D. H.-C., Chung, W., & Lee, C. (2023) · Journal of Neuro-Oncology · doi:10.1007/s11060-023-04452-x · Cited by 8
Brain metastasis in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations: a report of seven cases and literature review
Er, P., Zhang, T., Wang, J., Qingsong, P., & Ping, W. (2017) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0079 · Cited by 7
A Bayesian network meta-analysis of EGFR-tyrosine kinase inhibitor treatments in patients with EGFR mutation-positive non-small cell lung cancer
Yin, J., Huang, J., Ren, M., Tang, R., Xie, L., & Xue, J. (2024) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2024.06.004 · Cited by 6
Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond
Mitsudomi, T., & Suda, K. (2013) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s49603 · Cited by 6
Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report
Boukansa, S., Mouhrach, I., Agy, F. E., Bardai, S. E., Bouguenouch, L., Serraj, M., Amara, B., Ouadnouni, Y., Smahi, M., Alami, B., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0298721 · Cited by 5
First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation
Kempf, E., Lacroix, L., & Soria, J. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.06.002 · Cited by 5
Mutation patterns of epidermal growth factor receptor gene in non-small cell lung cancer among Egyptian patients
El-Metnawy, W., Qenawi, M., Sabet, S., & Bassiony, H. (2022) · Egyptian Journal of Basic and Applied Sciences · doi:10.1080/2314808x.2021.2022924 · Cited by 5
Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)
Zhang, B., Shi, C., Gao, Z., Zhong, H., Xiong, L., Gu, A., Wang, W., Chu, T., Zhang, W., Wang, H., et al. (2022) · BMC Cancer · doi:10.1186/s12885-022-09409-3 · Cited by 4
Effective treatment with icotinib in advanced lung adenocarcinoma harboring rare EGFR mutation G719A/L833V: A case report
Zhou, B., Wang, Y., Liao, H., & Li, B. (2022) · Medicine · doi:10.1097/md.0000000000030080 · Cited by 4
Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
Thomas, D. B., Maloney, M. E., & Raval, G. G. (2023) · Cureus · doi:10.7759/cureus.48122 · Cited by 5
Two Cases of Non–Small-Cell Lung Cancer with Rare Complex Mutation of EGFR Exon 18 But Different Response to Targeted Therapy
Gauthier, H., Douchet, G., Lehmann‐Che, J., Meignin, V., Donzel‐Raynaud, C., Sabatier, P., de Crémoux, H., Poirot, B., Culine, S., Pouessel, D., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000328 · Cited by 4
Epidermal Growth Factor Receptor Mutation Status and the Impact on Clinical Outcomes in Patients with Non-Small Cell Lung Cancer
Hm, H., wei, Y., Wang, J., Ran, F., Wen, Y., Chen, Q., & Bf, Z. (2022) · Balkan Journal of Medical Genetics · doi:10.2478/bjmg-2022-0015 · Cited by 4
[A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer with Uncommon EGFR Mutations].
Du, W., Wo, Y., Lu, T., Wang, Y., & Jiao, W. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.09.07 · Cited by 3
Proteogenomic analysis of air-pollution-associated lung cancer reveals prevention and therapeutic opportunitiesPreprint
Zhang, H., Liu, C., Wang, S., Wang, Q., Xu, F., Jiang, H., Zhang, Y., Su, X., & Li, G. (2024) · eLife · doi:10.7554/elife.95453.2 · Cited by 7
Epidermal growth factor receptor (EGFR) atypical mutations in non-small-cell lung cancer (NSCLC): ‘Where the streets have no name’
Spitaleri, G., Aliaga, P. T., Mariani, G. A., Attili, I., Signore, E. D., Corvaja, C., Napoli, V. M., Cavallone, M., Etessami, J. D., Zhan, Y., et al. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105327 · Cited by 2
Evolution and Functional Divergence of the ERBB Receptor Family
Wu, S., Haltom, J., Zhao, W., Yang, J., Zhou, Z. M., & Gu, X. (2021) · Pharmacogenomics · doi:10.2217/pgs-2020-0158 · Cited by 2
Biomarkers/Molecular Targets, Immunotherapy, and Treatments for Non–Small Cell Lung Cancer
Waxman, E. S., & Fossella, F. V. (2016) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2016.7.5.4 · Cited by 3
Predictive Tumor Biomarkers for EGFR Inhibitors
Kim, L., Liu, G., & Tsao, M. (2014) · Lung Cancer · doi:10.1002/9781118468791.ch28 · Cited by 2
Two Distinct Primary EGFR-Mutated Lung Adenocarcinoma Within the Same Patient: A Case Report
Ahmad, J. A. N., He, B., Schroeder, B., & Rosales, J. (2022) · International Journal of Cancer Care and Delivery · doi:10.53876/001c.37213 · Cited by 1
What is the best first-line combination regimen for advanced EGFR-mutated non-small cell lung cancer: a network meta-analysis and systemic review
Yang, C., Wang, Y., Sun, Y., Sun, Y., Zhang, R., Wang, C., Song, Y., Zhao, W. H., & Li, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1572115 · Cited by 1
A 78-Year-Old Woman with Brain Metastases
Tafe, L. J., & Tsongalis, G. J. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.229864 · Cited by 2
Adenocarcinoma of the Lung with Miliary Metastases and Primary Resistance Exon 20 Mutations
Hsu, F. (2018) · Cureus · doi:10.7759/cureus.3533 · Cited by 1
The effectiveness of sequential afatinib and furmonertinib in an advanced lung adenocarcinoma with rare compound EGFR mutation (L833V/H835L)
Pan, Y., Yan, L., Gu, Y., Wang, S., Li, H., Yu, P., & Chen, Q. (2025) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001692 · Cited by 1
Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report
Wu, L., Fang, C., Zhao, W., Li, D., Tang, S., Li, X., & Ji, M. Q. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-95 · Cited by 1
Gefitinib: Re-Emerging from the Shadows
Martin, P., Owen, S. P., & Leighl, N. B. (2013) · Lung Cancer Management · doi:10.2217/lmt.13.42
Synthetic lethality in NSCLC cells: Interrogating the therapeutic potential of ATM deficiency
Elegbede, A. A. (2014) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/27960
The role of epidermal growth factor receptor in non-small cell lung cancer Epidermal growth factor reseptorünün küçük hücreli olmayan akciğer kanserindeki rolü
Nursal, F. (2015)

Authors: Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Corresponding author: Papadimitrakopoulou, Vassiliki
ORCID: Massarelli, Erminia
Johnson, Faye M.
Wistuba, Ignacio I.
Papadimitrakopoulou, Vassiliki
Venue: Lung Cancer
Publisher: Elsevier BV
Published: 2013-06
Volume: 80
Issue: 3
Pages: 235-241
ISSN: 0169-5002 (ISSN-L)
DOI: 10.1016/j.lungcan.2013.01.018
OpenAlex: W2014993624
Cited by: 110
References: 86
Citations by year: 2026: 2 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 16 · 2021: 8 · 2020: 11 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 10 · 2013: 4
FWCI: 1.56
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Lung Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords: EGFR mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, drug resistance, erlotinib, gefitinib, exon 19 deletion, L858R mutation, T790M mutation, targeted therapy
MeSH terms: Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Exons, Humans, Point Mutation, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks